A phase 1/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndrome.

J Neurodev Disord · 2019 · PMC6676516 · PMID 31370779

Europe PMC DOI

hedged sentences

0.1400

closest p · 2.8× alpha

0.1400

boldest claim

The sentences

failed to reach significancep = 0.14not close (p > 0.1)

Change from screening to week 12 on the depressed mood subscale failed to reach significance ( t = − 1.54, p = 0.14, d = 0.37).

also in 4,113 other papers

failed to reach statistical significanceno p-value reported

Even those secondary endpoints that failed to reach statistical significance were still associated with moderate effect sizes ( d = 0.25 to 0.53).

also in 6,035 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.